IN8bio

NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...

NEW YORK, November 6, 2025 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell...